---
title: "Ionis to hold second quarter 2026 financial results webcast | IONS Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292756459.md"
description: "Ionis Pharmaceuticals (Nasdaq: IONS) announced it will host a live webcast on Wednesday, July 29 at 8:30 a.m. ET to discuss its second quarter 2026 financial results and highlight progress on key programs. A replay will be available for a limited time at the same address."
datetime: "2026-07-15T03:05:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292756459.md)
  - [en](https://longbridge.com/en/news/292756459.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292756459.md)
---

# Ionis to hold second quarter 2026 financial results webcast | IONS Stock News

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

_Webcast scheduled for Wednesday, July 29 at 8:30 a.m. Eastern Time_

CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, July 29 at 8:30 a.m. Eastern Time to discuss its second quarter 2026 financial results and highlight progress on key programs.

The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.

**About Ionis Pharmaceuticals, Inc.**

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260715218889/en/

**Ionis Investor Contact:**  
D. Wade Walke, Ph.D. – IR@ionis.com – 760-603-2331

**Ionis Media Contact:**  
Hayley Soffer – media@ionis.com – 760-603-4679

Source: Ionis Pharmaceuticals, Inc.

### Related Stocks

- [IONS.US](https://longbridge.com/en/quote/IONS.US.md)

## Related News & Research

- [Entropy Technologies LP Makes New $2.04 Million Investment in Ionis Pharmaceuticals, Inc. $IONS](https://longbridge.com/en/news/293897817.md)
- [Ionis Pharmaceuticals, Inc. $IONS Shares Acquired by California Public Employees Retirement System](https://longbridge.com/en/news/293717941.md)
- [Ionis announces Dr. Frank Bennett, chief scientific officer, to retire | IONS Stock News](https://longbridge.com/en/news/294199095.md)
- [Grandstand to Report 2026 Second Quarter Results on August 13 and Host Conference Call and Webcast | GRSD Stock News](https://longbridge.com/en/news/293950840.md)
- [HYSTER-YALE ANNOUNCES DATES OF SECOND QUARTER 2026 EARNINGS RELEASE AND WEBCAST | HY Stock News](https://longbridge.com/en/news/294050773.md)